{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4"},{"groupId":"OG001","value":"88.5"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"89.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"91"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.","groups":[{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG000","title":"Cohort 1 Vemurafenib"},{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG001","title":"Cohort 1 Placebo"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"OG002","title":"Cohort 2 Vemurafenib"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"OG003","title":"Cohort 2 Placebo"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"From randomization up to study completion or discontinuation (up until 13-July-2018, approximately 6 years)","title":"Percentage of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}